Ellen K. Ritchie

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes et al. · Journal of Clinical Oncology · 2018 · 958 citations · Full text

Mixed-phenotype Acute Leukemia, Pharmacotherapy, Metronomic Chemotherapy +16

Somatic mutations precede acute myeloid leukemia years before diagnosis

Pinkal Desai, Nuria Mencia-Trinchant, Oleksandr Savenkov et al. · Nature Medicine · 2018 · 600 citations

Somatic Variant, Somatic Mutations, Medicine +7

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

Alexander E. Perl, Jessica K. Altman, Jörge E. Cortes et al. · The Lancet Oncology · 2017 · 484 citations · Full text

Selective Inhibition, Hematological Malignancy, Oncology +6

Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study

Giovanni Martinelli, Nicolas Boissel, Patrice Chevallier et al. · Journal of Clinical Oncology · 2017 · 437 citations · Full text

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

Jörge E. Cortes, Philippe Rousselot, Dong‐Wook Kim et al. · Blood · 2006 · 417 citations